{"id":"W2605743022","doi":"10.1002/pbc.26414","title":"A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)","year":2017,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Children's Hospital","funders":"Hyundai Hope On Wheels; St. Baldrick's Foundation; American Cancer Society; Leukemia and Lymphoma Society; National Cancer Institute; Conquer Cancer Foundation; National Institutes of Health","keywords":"Plerixafor; Medicine; Cytarabine; Etoposide; Internal medicine; Chemotherapy; Oncology; Refractory (planetary science); Gastroenterology; CXCR4","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001836921,0.001839631,0.00180058,0.0004190711,0.0004095267,0.0007696893,0.001237353,0.001224811,0.002457783],"category_scores_gemma":[0.0008226046,0.0007572114,0.001142159,0.000428857,0.001172561,0.0006827338,0.0004199483,0.003775223,0.0006079053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062251,"about_ca_system_score_gemma":0.002156998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001364194,"about_ca_topic_score_gemma":0.00332107,"domain_scores_codex":[0.9992781,0.0004232232,0.00003111869,0.0000925308,0.00006490443,0.0001101477],"domain_scores_gemma":[0.9992113,0.0001486557,0.0001897352,0.00005915147,0.0000353285,0.0003556919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4619884,0.271934,0.01781257,0.001419404,0.002396232,0.001373649,0.001022995,0.00620368,0.09025275,0.0006042904,0.006029407,0.1389625],"study_design_scores_gemma":[0.4170382,0.5600381,0.01336665,0.00003988815,0.0003738926,0.0005863592,0.00007853429,0.0008165787,0.005092814,0.00009522226,0.002450903,0.00002278551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957548,0.0009490613,0.0003396622,0.000300098,0.00004566194,0.001490246,0.000446015,0.00004092505,0.0006333417],"genre_scores_gemma":[0.9875749,0.002195637,0.00262454,0.0007258563,0.0001789463,0.00307095,0.002174338,0.00003358141,0.001421354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002457783,"threshold_uncertainty_score":0.009714723,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02515996934754412,"score_gpt":0.3226069318202358,"score_spread":0.2974469624726916,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}